OptimizeRx (NASDAQ:OPRX) vs. Synopsys (NASDAQ:SNPS) Head-To-Head Analysis

Synopsys (NASDAQ:SNPS) and OptimizeRx (NASDAQ:OPRX) are both computer and technology companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Institutional and Insider Ownership

85.5% of Synopsys shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 0.6% of Synopsys shares are owned by insiders. Comparatively, 5.6% of OptimizeRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Synopsys and OptimizeRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synopsys	13.76%	6.83%	3.93%
OptimizeRx	4.69%	10.61%	7.54%

Risk & Volatility

Synopsys has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500.

Earnings and Valuation

This table compares Synopsys and OptimizeRx”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synopsys	$7.05 billion	10.75	$1.33 billion	$6.44	61.48
OptimizeRx	$109.43 million	1.12	$5.13 million	$0.26	25.23

Synopsys has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Synopsys, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Synopsys and OptimizeRx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synopsys	1	8	8	0	2.41
OptimizeRx	1	1	6	1	2.78

Synopsys currently has a consensus price target of $531.00, suggesting a potential upside of 34.11%. OptimizeRx has a consensus price target of $17.57, suggesting a potential upside of 167.86%. Given OptimizeRx’s stronger consensus rating and higher possible upside, analysts plainly believe OptimizeRx is more favorable than Synopsys.

Summary

Synopsys beats OptimizeRx on 8 of the 15 factors compared between the two stocks.

About Synopsys

Synopsys, Inc. provides electronic design automation software products used to design and test integrated circuits. It operates in three segments: Design Automation, Design IP, and Software Integrity. The company offers Digital and Custom IC Design solution that provides digital design implementation solutions; Verification solution that offers virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions. It also provides intellectual property (IP) solutions for USB, PCI Express, DDR, Ethernet, MIPI, HDMI, and Bluetooth low energy applications; logic libraries and embedded memories; processor cores, software, and application-specific instruction-set processor tools for embedded applications; security IP solutions; IP solutions for automotive market; and system-on-chip (SoC) infrastructure IP, datapath and building block IP, and verification IP products, as well as mathematical and floating-point components, and Arm AMBA interconnect fabric and peripherals. In addition, the company offers HAPS FPGA-based prototyping systems; virtual prototyping solutions; and Platform Architect solutions for SoC architecture analysis and optimization, as well as optical products, and mechatronic simulations. Further, it provides security and quality testing products, managed services, programs and professional services, and training that enable its customers to detect and remediate security vulnerabilities, and defects in the software development lifecycle, as well as manufacturing solutions. Additionally, the company provides intelligent orchestration solution, software risk manager, and black duck software composition analysis tools. It serves electronics, financial services, automotive, medicine, energy, and industrial areas. The company was incorporated in 1986 and is headquartered in Sunnyvale, California.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.